

THE TITAN STENT : DATA FROM A NATIONAL REGISTRY

BACKGROUND

Five to fifteen percent of the population have an allergy to nickel, chromium or molybdenum, which may be responsible for inducing restenosis.


The Titan stent is a balloon-expandable stent made of stainless steel and coated with Titanox* which completely prevents discharge of nickel, chromium and molybdenum.

PURPOSE AND METHODS

- Assess the short and long term characteristics of the Titan stent in a multi-center national registry (9 centers).
- This real life study included all patient candidates for stent implantation. Choosing of the Titan stent was at the operator's discretion with no exclusion criteria.
- A clinical research form was completed for each patient at the end of the procedure. Thirty days and 6 months later, a phone-call follow up was performed by an independent research nurse.
- Clinical data included gender, age, risk factors and clinical presentation.
- PCI data included lesion classification, deployment pressure.
- Outcome data included immediate technical and clinical success and complications, and major adverse cardiac events (including sub-acute thrombosis, MI, TLR and death) at 30 days and 6 months.

RESULTS

- From 4/2003 to 11/2003 a total of 103 stents were implanted in 100 patients (mean age 61.1 years, 81 males).
- Risk factors included hypertension (52), Diabetes Mellitus (35), hypercholesterolemia (63), current smoking (23), and family history (12 patients).
- 67 patients were catheterized for acute coronary syndromes.
- 52 patients had lesions defined as type B2 or C.
- Procedure and immediate outcome: high pressure deployment (>12 atmospheres) was used in 57 patients. **Successful deployment and procedure were achieved in 100% of patients.**
- Satisfaction of operators: the performances of the delivery system and stent was high for all parameters including, Deployment, Flexibility, Expansion and Visualization.
- **30 days & 180 days follow-up:** during the first 30 days there were no major adverse cardiac events (MACE) including sub-acute thrombosis, MI, TLR and death. At 180 days MACE rate was remarkably low with only 3% TVR.



MACE

Type	30 days (%)	180 days (%)
Death	0	0
TLR-PCI	0	1
TLR-CABG	0	2
QWMI	0	0
NQWMI	0	0
Total	0	3

FUNCTIONAL CLASS

Type	30 days (%)	180 days (%)
Class I	90	95
Class II	6	3
Class III	4	2
Class IV	0	0

* Titanox is a registered trademark of Hexacath for its proprietary Titanium-Nitride-Oxide Coating.

THE TITAN STENT : DATA FROM A NATIONAL REGISTRY

CONCLUSION

The Titan stent has a remarkable safety profile and can be used in complex coronary lesions.
The immediate, short and long term results are excellent.

THE ISRAELI WORKING GROUP FOR INTERVENTIONAL CARDIOLOGY

Hadassah Medical Center - Jerusalem	M Mosseri
Nahariya Hospital - Nahariya	M Brizines
Ziv Hospital - Zfat	M Flich
Hillel Yaffe Medical Center - Hadera	A Frimerman
Sheba Hospital - Tel Aviv	V Guetta
Poria Hospital - Tiberias	Y Hasin
Barzilay Hospital - Ashkelon	J Jeffery
Ichilov Hospital - Tel Aviv	H Miller
Wolfson Hospital - Holon	I Tamari
Hadassah Medical Center - Jerusalem	C Lotan

No contractual document - 01/2006

Publication : Cardiovascular Revascularization medicine, 2005.
"Short and long-term outcomes of the titanium-NO stent registry"



4, Passage Saint Antoine
92508 Rueil-Malmaison Cedex - France
Tél. +33 (0)1 41 39 01 91
Fax. +33 (0)1 41 39 01 93

www.hexacath.com



Scientific Symposia
Novel Stent Designs
and Innovative DES systems

Speaker: Morris Mosseri
Moderators: Andrew J. Carter, Julio C. Palmaz